HX035

HX035 is a designation associated with two distinct therapeutic candidates. The first is a **bispecific or multi-specific monoclonal antibody** developed by **Helex** using its proprietary **autoRx40 Platform**. This biologic targets the **OX40 (CD134)** pathway and is designed for the treatment of complex **autoimmune diseases**. Its mechanism involves inhibiting immune signaling while simultaneously depleting pathogenic immune cells to restore immune homeostasis. The second entity is a **35 kDa hyaluronan fragment** (also known as **HA35** or **HX035**) developed by **Nakhia Impex LLC**. This low molecular weight polysaccharide is administered via deep subcutaneous injection into the abdominal adipose layer. It has been evaluated in clinical trials (e.g., NCT03240068) as a palliative therapy to alleviate pain and discomfort in patients with **advanced lung cancer**, leveraging the unique tissue-permeable and signaling properties of specific hyaluronan fragments.

Other names

35 kDa hyaluronan fragment35kDa hyaluronanHA35 hyaluronanHA-35 hyaluronanHA 35 hyaluronan